![]()
|
|
||||||||
J. Biol. Chem., Vol. 278, Issue 6, 4205-4215, February 7, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§¶,
,
,
**,
§,
, and
§
From the Annexin II is secreted into the extracellular
environment, where, via interactions with specific proteases and
extracellular matrix proteins, it participates in plasminogen
activation, cell adhesion, and tumor metastasis and invasion. However,
mechanisms regulating annexin II transport across the cellular membrane
are unknown. In this study, we used coimmunoprecipitation to show that
Annexin-II was bound to insulin and insulin-like growth factor-1 (IGF-1) receptors in PC12 cells and NIH-3T3 cells overexpressing insulin (NIH-3T3IR) or IGF-1 receptor
(NIH-3T3IGF-1R). Stimulation of insulin and IGF-1 receptors
by insulin caused a temporary dissociation of annexin II from these
receptors, which was accompanied by an increased amount of
extracellular annexin II detected in the media of PC12,
NIH-3T3IR, and NIH-3T3IGF-1R cells but not in
that of untransfected NIH-3T3 cells. Activation of a different growth
factor receptor, the platelet-derived growth factor receptor, did not
produce such results. Tyrphostin AG1024, a tyrosine kinase inhibitor of
insulin and IGF-1 receptor, was shown to inhibit annexin II secretion
along with reduced receptor phosphorylation. Inhibitors of a few
downstream signaling enzymes including phosphatidylinositol 3-kinase,
pp60c-Src, and protein kinase C had no effect on insulin-induced
annexin II secretion, suggesting a possible direct link between
receptor activation and annexin II secretion. Immunocytochemistry
revealed that insulin also induced transport of the membrane-bound form
of annexin II to the outside layer of the cell membrane and appeared to
promote cell aggregation. These results suggest that the insulin
receptor and its signaling pathways may participate in molecular
mechanisms mediating annexin II secretion.
Laboratory of Adaptive Systems, NINDS,
National Institutes of Health, Bethesda, Maryland 20892, § Blanchette Rockefeller Neurosciences Institutes,
Rockville, Maryland 20850,
Diabetes Unit, LCI, NCCAM, National
Institutes of Health, Bethesda, Maryland 20892, and the
** Department of Experimental and Applied Pharmacology,
University of Pavia, Pavia, Italy
This article has been cited by other articles:
![]() |
S.-H. Oh, W.-Y. Kim, J.-H. Kim, M. N. Younes, A. K. El-Naggar, J. N. Myers, M. Kies, P. Cohen, F. Khuri, W. K. Hong, et al. Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., January 15, 2006; 12(2): 653 - 661. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. N. Lee, N. Jamgotchian, S. G. Allen, F. W. K. Kan, and I. L. Hale Annexin A2 heterotetramer: role in tight junction assembly Am J Physiol Renal Physiol, September 1, 2004; 287(3): F481 - F491. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Rescher and V. Gerke Annexins - unique membrane binding proteins with diverse functions J. Cell Sci., June 1, 2004; 117(13): 2631 - 2639. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Huang, S. H. Hsia, T. Imamura, I. Usui, and J. M. Olefsky Annexin II Is a Thiazolidinedione-Responsive Gene Involved in Insulin-Induced Glucose Transporter Isoform 4 Translocation in 3T3-L1 Adipocytes Endocrinology, April 1, 2004; 145(4): 1579 - 1586. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |